Our findings suggested that E2F1/2/5/8 were potential therapeutic targets for LC, and transcriptional E2F3/6/7 were potential prognostic markers for the improvement of LC survival and prognostic accuracy. This evidence concerns the gene E2F1 and laryngotracheoesophageal cleft.